Replies to post #52107 on $heff's $tation of $tocks & $olid DD

[Investor100]

RGEN:CORRECTING and REPLACING Repligen Announces Submission of Marketing Authorization Application in EU for SecreFlo™ to Improve Pancreatic Imaging in Patients with Pancreatitis

- Follows on U.S. FDA Grant of Priority Review for SecreFlo™ NDA -


Please replace the forward looking statement with the following corrected version.

The corrected release reads:

REPLIGEN ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATION IN EU FOR SECREFLO™ TO IMPROVE PANCREATIC IMAGING IN PATIENTS WITH PANCREATITIS

- Follows on U.S. FDA Grant of Priority Review for SecreFlo™ NDA -

http://finance.yahoo.com/news/repligen-announces-submission-marketing-authorization-120000674.html

Investor 100